Selection of disease-modifying therapy for older patients with SMA currently involves choosing between nusinersen and risdiplam based on administration considerations, access to medical facilities ...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 eu ...

ricochet64 via Shutterstock. Roche has won approval in Europe for a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam), as the drugmaker looks to extend its growing ...